Document Type: Original Article

Authors

1 Department of Headache, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Department of Headache, Neurology Ward, Sina University Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Headache, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

3 Headache Ward, Iranian Neurological Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Department of Neurology, School of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

4 Department of Geriatric Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran Memory and Behavioral Neurology Division, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran

5 Headache Ward, Iranian Neurological Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Department of Neurology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

6 Headache Ward, Iranian Neurological Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Department of Neurology, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran

7 Cardiovascular Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran Department of Cardiology, School of Medicine, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran

8 Headache Ward, Iranian Neurological Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Headache is among the most common disabling neurologic disorders. We measured quality of life in chronic migraine (CM) and episodic migraine (EM), stratified by medication overuse headache (MOH) and presence of aura.
Methods: In this observational study, conducted from January 2016 to December 2018, adult patients referred to the tertiary headache clinic of Sina Hospital in Tehran, Iran, who met International Classification of Headache Disorders, 3rd Edition-beta (ICHD-3 β) criteria for migraine were classified to EM and CM subtyped based on presence of aura and MOH. Validated Farsi versions of Migraine Disability Assessment Scale (MIDAS) and 6-item Headache Impact Test (HIT-6) questionnaires were used.
Results: A total of 2454 patients (1907 women) were enrolled from which 1261 (51.4%) patients had EM and 1193 (48.6%) had CM, while 908 subjects (37.0%) had MOH, of whom 890 (98.0%) had CM. Median scores of MIDAS and HIT-6 were significantly higher in patients with CM compared to EM sufferers. Chronic migraineurs with MOH had a significantly higher median score of MIDAS and HIT-6 compared to patients with non-MOH CM. Also, there was a moderate positive correlation between MIDAS (disability) and HIT-6 scores (impact on patients’ life) and a moderate correlation between HIT-6 and pain severity.
Conclusion: The results of this study confirm that CM and MOH are associated with a higher headache-related disability and impact on life compared to EM. Therefore, treatment goals in prevention of MOH and migraine transformation warrant higher quality of life in patients with migraine.

Keywords

  1. ICHD-3 Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38(1): 1–211.
  2. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: An epidemiological study. Cephalalgia 1992; 12(4): 221-8.
  3. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J. Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol 1995; 24(3): 612-8.
  4. Manzoni GC, Torelli P. Epidemiology of migraine. J Headache Pain 2003; 4(1): s18-s22.
  5. Lipton RB, Manack AA, Buse DC, Fanning KM, Reed ML. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: Demographics and Headache-Related Disability. Headache 2016; 56(8): 1280-9.
  6. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia 2010; 30(5): 599-609.
  7. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053): 1545-602.
  8. Global Health Data Exchange (GHDX). Global Burden of Disease Study 2017 (GBD 2017) Data Resources [Online]. [cited 2018]; Available from: URL: http://ghdx.healthdata.org/gbd-2017
  9. Nachit-Ouinekh F, Dartigues JF, Henry P, Becg JP, Chastan G, Lemaire N, et al. Use of the headache impact test (HIT-6) in general practice: Relationship with quality of life and severity. Eur J Neurol 2005; 12(3): 189-93.
  10. Shin HE, Park JW, Kim YI, Lee KS. Headache Impact Test-6 (HIT-6) scores for migraine patients: Their relation to disability as measured from a headache diary. J Clin Neurol 2008; 4(4): 158-63.
  11. Sauro KM, Rose MS, Becker WJ, Christie SN, Giammarco R, Mackie GF, et al. HIT-6 and MIDAS as measures of headache disability in a headache referral population. Headache 2010; 50(3): 383-95.
  12. Benz T, Lehmann S, Gantenbein AR, Sandor PS, Stewart WF, Elfering A, et al. Translation, cross-cultural adaptation and reliability of the German version of the migraine disability assessment (MIDAS) questionnaire. Health Qual Life Outcomes 2018; 16(1): 42.
  13. Shaik MM, Hassan NB, Tan HL, Bhaskar S, Gan SH. Validity and reliability of the Bahasa Melayu version of the Migraine Disability Assessment questionnaire. Biomed Res Int 2014; 2014: 435856.
  14. Magnoux E, Freeman MA, Zlotnik G. MIDAS and HIT-6 French translation: Reliability and correlation between tests. Cephalalgia 2008; 28(1): 26-34.
  15. D'Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, et al. The Migraine Disability Assessment (MIDAS) questionnaire: Translation and reliability of the Italian version. Cephalalgia 2001; 21(10): 947-52.
  16. Juyal R, Verma R, Garg RK, Shukla R, Agarwal A, Singh MK. Reliability and validity of Hindi translation of the migraine disability assessment and headache impact test-6 questionnaires. Ann Indian Acad Neurol 2010; 13(4): 276-83.
  17. Zandifar A, Banihashemi M, Haghdoost F, Masjedi SS, Manouchehri N, Asgari F, et al. Reliability and Validity of the Persian HIT-6 Questionnaire in Migraine and Tension-type Headache. Pain Pract 2014; 14(7): 625-31.
  18. Zandifar A, Asgari F, Haghdoost F, Masjedi SS, Manouchehri N, Banihashemi M, et al. Reliability and validity of the migraine disability assessment scale among migraine and tension type headache in Iranian patients. Biomed Res Int 2014; 2014: 978064.
  19. Ertas M, Siva A, Dalkara T, Uzuner N, Dora B, Inan L, et al. Validity and reliability of the Turkish Migraine Disability Assessment (MIDAS) questionnaire. Headache 2004; 44(8): 786-93.
  20. Kim BK, Chung YK, Kim JM, Lee KS, Chu MK. Prevalence, clinical characteristics and disability of migraine and probable migraine: A nationwide population-based survey in Korea. Cephalalgia 2013; 33(13): 1106-16.
  21. Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011; 31(3): 301-15.
  22. Bayliss M, Batenhorst A. The HIT-6™: A user's guide. Lincoln, RI: QualityMetric, Inc: 2002.
  23. Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. Handbook of pain assessment. 2nd. New York, NY: The Guilford Press; 2001. p. 15-34.
  24. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012; 52(10): 1456-70.
  25. Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: A clinic-based study in Taiwan. Cephalalgia 2013; 33(3): 171-81.
  26. Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D'Amico D. Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci 2004; 25(Suppl 3): S105-S107.
  27. Leonardi M, Raggi A, Bussone G, D'Amico D. Health-related quality of life, disability and severity of disease in patients with migraine attending to a specialty headache center. Headache 2010; 50(10): 1576-86.
  28. Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia 2015; 35(7): 563-78.
  29. Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK. A Real-World Analysis of Migraine: A Cross-Sectional Study of Disease Burden and Treatment Patterns. Headache 2017; 57(10): 1532-44.
  30. Rojo E, Pedraza MI, Munoz I, Mulero P, Ruiz M, de la Cruz C, et al. Chronic migraine with and without medication overuse: experience in a hospital series of 434 patients. Neurologia 2015; 30(3): 153-7.
  31. Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia 2011; 31(3): 357-67.